# Clinical Pharmacology, Drug Action and Pharmacogenetics

> **NIH NIH T32** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $608,766

## Abstract

ABSTRACT/PROJECT SUMMARY
The world has recently witnessed unprecedented advances in biomedical research and discovery. We have
observed technological miracles including isolation of human embryonic stem cells, completion of the human
genome project, generation of new heart valves from stem cells and the discovery of novel genetic risk factors
through genome-wide screens. With the rapid development and application of new technologies to biomedical
research, enormous progress has been made in understanding basic human biology and disease. However,
the translation of this knowledge to the discovery, development and optimal use of pharmacological therapies
has not kept pace. This slow progress can be attributed, primarily, to two factors: 1) a severe shortage of well
trained, qualified clinical pharmacology investigators, nationally, who can fulfill this need for translational
research and, 2) a marked contraction of training opportunities within the U.S.
At UCSF, we are keenly aware of what has been described as an “overwhelming mandate” to train the next
generation of clinical pharmacologist researchers. We are uniquely positioned to fulfill the growing and evolving
needs of adult and pediatric clinical pharmacology through the recruitment of a diverse and highly motivated
pool of M.D., Pharm.D. and Ph.D. trainees into our research-intensive Clinical Pharmacology and Therapeutics
Postdoctoral Training Program (https://pharm.ucsf.edu/cpt). For the past 54 years, the UCSF Clinical
Pharmacology Training program has consistently produced clinical pharmacologists of the highest caliber. In
this competing renewal application, we propose to continue and extend our highly successful clinical
pharmacology-training program, which includes seven two-year fellowship positions. Our fellows will be
educated in translational research – from basic science to clinical application – through our mentored research
training, didactic coursework and participation in a biweekly seminar series. Faculty mentors in the program,
committed to training our fellows, have high impact, NIH-funded research programs and teaching careers. Drs.
Burchard and Floren lead the program. Dr. Burchard, M.D., M.P.H., studies genetics and pharmacogenetics in
minority children. Dr. Burchard served as an advisor to the Director for the National Institutes of Health's “All of
Us” initiative. Dr. Floren, PharmD., is the Director of Advanced Scientific and Clinical Training for the UCSF
PharmD program.
Our research strengths include pediatric pharmacology, vulnerable populations, pharmacogenomics,
pharmacometrics, systems pharmacology and regulatory sciences. Our program will help create a well-trained
and diverse group of clinical-scientist investigators who will serve as tomorrow's leaders in clinical
pharmacology research and practice in academia as well as the pharmaceutical, biotechnology industries and
regulatory agencies.

## Key facts

- **NIH application ID:** 9854617
- **Project number:** 2T32GM007546-44
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Esteban Gonzalez Burchard
- **Activity code:** T32 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $608,766
- **Award type:** 2
- **Project period:** 1977-07-01 → 2025-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9854617

## Citation

> US National Institutes of Health, RePORTER application 9854617, Clinical Pharmacology, Drug Action and Pharmacogenetics (2T32GM007546-44). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9854617. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*